Conga Announces Intent to Acquire PROS B2B Business Following its Acquisition by Thoma Bravo
1.10.2025 13:35:00 CEST | Business Wire | Press Release
Conga, a leader for AI-powered innovation in configure, price, quote (CPQ), contract lifecycle management (CLM), and document automation, today announced it has agreed to binding preliminary terms to acquire the B2B business of PROS Holdings, Inc. (NYSE: PRO) (“PROS”) from certain investment funds affiliated with Thoma Bravo. Conga expects a definitive agreement regarding the acquisition of PROS’ B2B business to be finalized in connection with the closing of Thoma Bravo’s acquisition of PROS and further expects that its acquisition of the B2B business will close in Q1 2026 (all timing subject to customary conditions, including receipt of regulatory approvals).
“Today marks a defining moment for B2B revenue optimization," said Dave Osborne, CEO at Conga. "For too long, companies have been forced to stitch together multiple point solutions across their revenue lifecycle, creating gaps, inefficiencies, and missed opportunities. This isn't just about combining two great companies—it's about fundamentally changing how businesses optimize revenue and eliminate complexity. Our customers will now have visibility and control over their entire revenue process, powered by AI that actually delivers measurable results."
AI is redefining how businesses compete, win, and grow, but fragmented systems continue to slow commercial progress. When pricing, quoting, and contracting are siloed, intelligent commerce becomes nearly impossible. This strategic combination will bring together two market leaders with complementary solutions to solve that challenge, enabling the first fully integrated, AI-powered platform that enables commercial excellence and is designed to help companies maximize revenue and customer lifetime value.
“We have followed the PROS story for many years and are excited to combine PROS’ B2B business with Conga, an existing Thoma Bravo portfolio company,” said Holden Spaht, a Managing Partner at Thoma Bravo. “This move will unlock a powerful product portfolio that expands on the offerings each company can deliver. It will unify critical revenue functions across pricing, quoting and contracting with speed and intelligence at a time when protecting, managing and growing revenue has never been more critical.”
Customers of both companies will gain more value than ever before with deeper AI-powered insights, streamlined workflows, and faster execution across the entire revenue lifecycle. With a unified, end-to-end platform, businesses will be able to operate with speed, intelligence, and agility without compromising on capabilities:
- Accelerated Revenue Processes: Seamlessly configure complex products, optimize pricing, and streamline quoting, contracting, and post-quote processes.
- AI-Driven Insights: Utilizing an ensemble of purpose-built algorithms and models, proven AI capabilities drive measurable results in price optimization, rebate management, intelligent CPQ, and contract lifecycle management.
- Seamless Post-Quote Execution: Integrated CLM, document automation, order management, and billing eliminate friction and manual effort across the contract lifecycle, and surface interaction points to improve revenue.
- Modular & Open Architecture: Built for flexibility, the combined platform will be designed to scale with businesses while seamlessly adapting to existing commercial processes and integrating into existing IT technology landscapes.
Enhanced Value for All Stakeholders
Following the closing of the transaction, the combined Conga and PROS B2B business will work to deliver enhanced product capabilities with minimal disruption as integration progresses, while providing existing Conga and PROS B2B customers with the same high level of service they have come to expect.
"This intended combination will bring together two organizations that share core values around customer success, innovation, and growth," added Osborne. "Our teams are excited to deliver the enhanced capabilities our customers have been requesting while creating new opportunities for our combined team."
Osborne will serve as CEO of the combined Conga and PROS B2B business following the transaction close.
About Conga
Conga partners with leading companies around the world to accelerate their journey to become a more connected, intelligent business. Conga brings Configure, Price, Quote, Contract Lifecycle Management, and Document Automation capabilities together on a single open platform that works with any ERP, any CRM, and any Cloud. Powered by a unified data model and purpose-built AI, Conga helps companies achieve a unique advantage—one built on seamless connection, actionable intelligence, and scalable growth.
Conga delivers an advantage to over 10,000 customers and 6.4 million users around the world. More than 7 million contracts and 46 million quotes are generated annually with Conga. Visit conga.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251001487006/en/
Contacts
Media Contact
PAN for Conga
Conga@pancomm.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom